Long-acting injectable (LAI) antipsychotic formulations are increasingly used for improving patient compliance and long-term outcomes. Transitioning to LAIs raises questions regarding how optimum efficacy can be rapidly achieved while minimizing potential efficacy and safety concerns related to overlapping plasma levels of prior treatments and the new LAI. Ideally, randomized clinical trials would provide guidance regarding transition algorithms, but the number of studies and sample size required to address relevant questions makes this approach unachievable. We have used quantitative systems pharmacology, a clinically calibrated, mechanism-based computer model for schizophrenia to identify optimal switching scenarios to injectable paliperidone palmitate oncemonthly (PP1M) from oral antipsychotics. We show that starting PP1M 1 day after the last oral medication dose or 4 weeks after the last LAI injection provides optimal benefit-risk compared to a delayed PP1M start after 1 week with either a 1-or 2-week overlap with oral paliperidone. Although a similar or better therapeutic effect can be achieved within 2 weeks for oral medications and LAI haloperidol decanoate and 8 weeks for LAI aripiprazole, we identified a potential transient undertreatment liability in all cases except for risperidone. Switching from oral olanzapine may lead to a small reduction of antipsychotic efficacy in some patients. Switching to PP1M decreases extrapyramidal symptom liability in most cases, but increased dopamine D 2 receptor inhibition (except for haloperidol) might potentially increase prolactin synthesis. Overall, these results suggest time-windows for which the treating clinician must be most vigilant for potential efficacy and safety signals when switching to PP1M.
Introduction
Increasingly, long-acting injectable (LAI) antipsychotic treatments are recognized as important for enhancing patient compliance as part of good treatment management of schizophrenia (Correll, 2014) . Poor adherence, particularly among those early in the course of their illness, leads to worse long-term outcomes than does consistent, well-documented treatment (Subotnik et al., 2011) . Despite the clinical benefits of LAIs, numerous challenges remain for their adoption into general psychiatric practice (Kane, 2014; Weiden et al., 2015) . It takes months for LAIs to achieve steady-state equilibrium, and knowing how to quickly transition patients from prior treatments to optimal doses of a new LAI regimen can be difficult. A good switching paradigm is important for preventing patients from being exposed to either excessive or inadequate concentrations of antipsychotics during the period of transition.
Performing clinical trials to identify optimal switching paradigms is impractical due to the large number of patients needed to address the multitude of potential switching options and dosing variants. Fortunately, pharmacokinetic (PK) interactions between antipsychotics are not common (see Supplementary information, Section S1). On the other hand, complex nonlinear pharmacodynamic (PD) interactions related to the rich and differential pharmacology of the many antipsychotic treatment options are likely. These differing pharmacologic profiles have important implications at the level of neuronal circuits and are challenging to quantify. For instance, combining other antipsychotics with aripiprazole often results in lower than anticipated clinical efficacies since switching between them involves competition between a full dopamine D 2 receptor (D 2 R) antagonist and a partial D 2 R agonist (aripiprazole) (Kim et al., 2009; Takeuchi et al., 2009; Wisniewski and Robert, 2012; Takeuchi and Remington, 2013) . The level of competition depends on the relative concentration of the two drugs and their binding affinities. The resulting complex PD interactions can affect both efficacy outcome and side-effects, including motor symptoms and prolactin synthesis.
Statistical analyses of databases that include antipsychotic combinations often fail to identify PD interactions on efficacy and safety measures because of the limited number of representations for each unique drug-dose combination. A novel way to address this issue is to simulate different switching scenarios using quantitative systems pharmacology (QSP) modeling that reflects the neurophysiology, neuropathology, and neuropharmacology of different drugs in "virtual" schizophrenia patients. This requires a mechanism-based computer model that is well calibrated both for motor side-effects (Roberts et al., 2016) and clinical efficacy Spiros et al., 2017) using historical clinical trial data. Blinded prior predictive modeling work that is based on preclinical pharmacology has suggested that this platform can anticipate unexpected clinical outcomes for novel antipsychotic drugs Liu et al., 2014) .
In this article, we simulate different scenarios for switching to PP1M from oral risperidone, haloperidol, aripiprazole, and olanzapine, and from long-acting haloperidol decanoate (HALD) and aripiprazole extended-release injectable suspension (AERIS). The objective of this work was to provide guidance for practical and safe scenarios for switching from each of the alternative antipsychotics based on QSP modeling. Treatment of patients with PP1M was based on the recommended dosing regimen (first injection of 234 mg, followed by injections of 156 mg on days 8, 38, and 68, and every 30 days thereafter), thereby fixing the PK profile (Samtani et al., 2011) . Although in principle we can simulate many different tapering algorithms of the baseline antipsychotics, we focused here on comparing three simple scenarios (see Section 3.3). The PK parameters for each antipsychotic formulation were derived from publicly available data.
Materials and methods
The modeling approach is shown schematically in Fig. 1 . Initially, plasma PK profiles of the different drugs were calculated using previously established PK parameters for each of the paired drugs (Methods section 2.1). Plasma levels were then converted to functional intrasynaptic brain concentrations using published studies on positron emission tomography (PET) tracer displacement (Methods section 2.2). Nonlinear PD interactions were simulated in the QSP model for any combination of the two drugs at specific doses to generate look-up tables corresponding to Positive and Negative Syndrome Scale (PANSS) total and extrapyramidal symptom (EPS) liability. Prolactin increase is usually associated with the level of striatal D 2 R inhibition (Arakawa et al., 2010) . Therefore, we generated look-up tables for the combined level of striatal D 2 R inhibition using the functional intrasynaptic concentration of the two drugs. Timedependent changes in free intrasynaptic drug concentrations for each switching scenario were used to calculate anticipated changes in clinical readouts of PANSS total scores, EPS liability, and D 2 R inhibition using linear interpolation from these lookup tables with a time resolution of 24 h over 90 days and 360 days for a switch from oral and LAI antipsychotics, respectively.
Pharmacokinetics profile simulation
PK parameters for the different drugs are shown in Table 1 . Plasma concentrations C n (t) at t hours after the n-th dose D were determined by (Wakamatsu et al., 2013) :
where F is the bioavailability, D the dose, k a and k e the single-dose absorption and elimination rate constant, respectively, V d the volume of distribution, and τ the dosing interval.
The receptor competition model
The receptor competition model as previously described (Spiros et al., 2010; Athan Spiros, 2012) Fig. 1 . Modeling pipeline for determining optimal switching paradigm. Plasma profiles for each drug are derived using traditional PK calculations. A particular switching scenario is then implemented and plasma level changes are calculated, assuming no PK-PK interactions. Using historical PET imaging tracer experiments, these plasma levels are then converted into dynamic functional intrasynaptic drug concentrations. For each synapse in the QSP model, the resulting effect on postsynaptic receptor activation by the two drugs using their appropriate multitarget pharmacology profile is then calculated. The pharmacodynamic impact of the combination of the two drugs is then simulated using the mechanism-based QSP platform for PANSS total score, EPS, and D 2 R inhibition with the calculated activation changes in all receptors affected by the two drugs based on their appropriate affinity. postsynaptic receptor activation levels at dopaminergic, serotonergic, adrenergic, and cholinergic neurotransmitter synapses with up to four agents (such as two antipsychotics with their major metabolites) competing with the endogenous neurotransmitter at the same binding site.
We first calculated functional intrasynaptic target engagement for each antipsychotic at specific doses by simulating quantitative PET imaging displacement studies with D 2 -specific radiotracers. Similarly to the Hill equation, Rec Occ = plasma level / (plasma level + K i ), fitting the plasma level to the PET tracer displacement from experimental, we calculated the displacement of the relevant tracer as a function of drug concentration (in nM) in the dopaminergic receptor competition model and fitted to a similar Hill equation Rec Occ = conc / (conc + K′ i ), where K′ i corresponds to the functional intrasynaptic concentration that displaces 50% of the tracer. The ratio K′ i /K i is the conversion factor between plasma levels and functional intrasynaptic drug concentrations for that particular drug that incorporates brain penetration and bloodbrain barrier transporter interactions.
The same receptor competition model is used to simulate the changes in postsynaptic receptor activation when two antipsychotics and their metabolites compete with the endogenous neurotransmitter for the same binding site.
The quantitative systems pharmacology platform for schizophrenia
The QSP platform is a biophysically realistic computer model (Supplementary information, Section S2) of the neuromodulatory effects of catecholamine receptors on closed cortico-striatal-thalamocortical loops (Pirini et al., 2009) . It has been previously described as a model for EPS (Roberts et al., 2016) and symptoms as measured by PANSS total scores Spiros et al., 2017) .
Results

Drug plasma profiles
Using Eq. (1), PK profiles were calculated based on their PK parameters (Wakamatsu et al., 2013) . For PP1M, the labeled injection schedule was used (i.e., injections of 234 mg at day 1 and of 156 mg at day 8 and every 30 days thereafter) (Samtani et al., 2011; Samtani et al., 2013) . Because plasma PK do not necessarily reflect the brain PK as measured by PET imaging of radiotracer in the brain (Tauscher et al., 2002) , the PK clearance rates for the functional brain concentration of risperidone, paliperidone, and olanzapine were reduced by 37%, 37%, and 40%, respectively.
From plasma level to free intrasynaptic functional drug concentration
The next step relates plasma concentrations of antipsychotics to functional brain levels. For many antipsychotics, PET imaging studies of specific D 2 R radiotracers, such as 11 C-raclopride (see Supplementary information, Table S1 ) are available. Using the strategy outlined in the Methods section 2.2, the conversion factors between plasma levels and intrasynaptic functional brain concentration were calculated ( ( Froemming et al., 1989 ) ( Mallikaarjun et al., 2013) 0.71 for paliperidone, 3.00 for olanzapine, 0.34 for aripiprazole, and 5.00 for haloperidol.
Scenarios for switching to paliperidone palmitate once-monthly
Three scenarios for switching to PP1M have been simulated (Fig. 3 ): (a) starting the first injection of PP1M the day following the last dose of the oral antipsychotic or 4 weeks after the last dose of HALD or AERIS; (b) starting on oral paliperidone for 1 week following the last dose of the oral antipsychotic or 4 weeks after the last dose of HALD or AERIS before initiating PP1M without overlap; and (c) starting on oral paliperidone for 2 weeks following the last dose of the oral antipsychotic or 4 weeks after the last dose of HALD and AERIS and transitioning to PP1M after 1 week of oral paliperidone resulting in 1 week of overlap.
Olanzapine
Simulated switches from patients on oral olanzapine 10, 15, and 20 mg to PP1M (Supplementary information, Section S4A) suggest that transitioning from olanzapine directly to PP1M provides the best clinical efficacy, corresponding to a maximal improvement in PANSS total score of 2 points compared to the 2-week transition through oral paliperidone with 1-week overlap; and 3.5 points compared to a 1-week prior lead-in with oral paliperidone. However, there is a transient period (2-3 weeks) after switching during which efficacy is much smaller. QSP simulations further suggest that during the first 90 days, motor side-effects on average would decrease by 5% and 7% compared to the overlap situations, when PP1M is immediately substituted for olanzapine. In contrast, the simulation for the D 2 R inhibition suggests that the direct transitioning to PP1M is about 3% and 5% greater with an associated increased risk for prolactin elevations.
Risperidone
Simulated switches from 2, 4, and 6 mg risperidone to PP1M identify direct transition to PP1M as the superior switching scenario for both clinical efficacy and motor side-effect outcomes (Supplementary information, Section S4B). Specifically, the maximal improvement on PANSS total scores was 1.4 points and 1.7 points better compared to the 2-week transition through oral paliperidone with 1-week overlap and the 1-week prior lead-in with oral paliperidone, respectively. The model predicts a 5% and 7% decrease in motor side-effects for the direct transition, compared with the other scenarios, but a 3% and 5% greater D 2 R inhibition with an associated risk for elevations in prolactin.
Haloperidol
QSP modeling predicts that switching from oral haloperidol 4 mg to PP1M would improve PANSS total scores by 2 points after 1 month and significantly reduce EPS liability by 65% (Fig. 4) . Because oral haloperidol is rapidly cleared from the brain, it is important that it be quickly replaced with PP1M. There is a 2-week period where the efficacy is lower by 3-4 points before reaching the same efficacy level as with haloperidol, whereas the two overlapping scenarios reach the same efficacy only at 3 weeks. D 2 R inhibition first decreases substantially before reaching a similar level as haloperidol 4 mg at 3 weeks (for immediate switching) and 4 weeks for switching with overlap.
Aripiprazole
Because of the unique pharmacology of aripiprazole (a relatively long half-life and partial D 2 R agonism, leading to negative PD interactions), QSP modeling predicts transient worsening (2.4 points on PANSS total score for an immediate transition to PP1M compared with 3.8 and 3.9 for the other switching scenarios) when switching from aripiprazole (Supplementary information, Section S4C). This period of low protection is resolved after 8 to 10 days. In addition, EPS liability is reduced substantially when switched to paliperidone with negligible differences between the three switching scenarios. D 2 R inhibition is much lower in the first week following transition to PP1M but increases thereafter, with the direct transition to PP1M predicted to produce slightly greater inhibition and associated risk for increased prolactin synthesis.
Switching from aripiprazole extended-release injectable suspension
QSP modeling predicts that switching from AERIS to PP1M may be associated with an immediate transient worsening of psychosis (about 1 point for 1 week on the PANSS total score with immediate switch to PP1M and 2 points for 2 weeks with the oral paliperidone overlap). However, it takes about 8 weeks before the efficacy is the same as the maximal clinical efficacy with AERIS (Fig. 5) . The modeling further predicts that EPS will substantially decline following transition to PP1M, but D 2 R inhibition increases compared to prior treatment with AERIS. As with prior comparisons, immediate transition to PP1M provides the strongest protection and the best reduction in EPS side-effects at the expense of somewhat higher D 2 R inhibition and, therefore, increased potential prolactin synthesis side-effects.
Switching from haloperidol decanoate
QSP simulations predict that directly transitioning from HALD to PP1M will be associated with a transient 2-point improvement in Fig. 3 . Simulated switching scenarios for oral antipsychotics with the existing oral comedication halted at week 0. (A) Simulated switching scenarios for long-acting antipsychotics with the last injection of the long-acting antipsychotics is given at week -4. (top row: 1-week overlap) Oral paliperidone 9 mg is started at week 0 for 1 week, while PP1M is started at week 1 with 234 mg and subsequent 156 mg injections; (middle row: 2-week overlap) 9 mg is started at week 0 for 2 weeks, while PP1M is started at week 1 with 234 mg and subsequent 156 mg injections; (bottom row: zero-week overlap) PP1M is started at week 0 with 234 mg and subsequent 156 mg injections, with no oral paliperidone. (B) Switching from oral medications. (top row: 1-week overlap) Oral paliperidone 9 mg is started at week 0 for 1 week, while PP1M is started at week 1 with 234 mg and subsequent 156 mg injections; (middle row: 2-week overlap) oral paliperidone 9 mg is started at week 0 for 2 weeks, while PP1M is started at week 1 with 234 mg and subsequent 156 mg injections; (bottom row: zero-week overlap) PP1M is started at week 0 with 234 mg and subsequent 156 mg injections, with no oral paliperidone.
B. Switch from Oral Antipsychotics to PP1M
PANSS total score compared with a 1.5-and 1.3-point transient worsening for 10 days following the other switching scenarios (Supplementary information, Section S4D). The maximal clinical efficacy following switch from HALD is achieved after 4 weeks with direct transition to PP1M and 5 weeks with the overlap scenarios. In all simulations, switching to PP1M substantially reduced motor side-effects (~65%). This is likely related to increased 5-HT 2A antagonism with paliperidone treatment. Inhibition of the D 2 R is also predicted to decrease following transition to PP1M (up to 15%), suggesting a possible beneficial impact on prolactin levels.
Discussion
Problems with adherence, tolerability, or efficacy may lead patients and their clinicians to switch from current antipsychotic treatment to PP1M (Kane, 2014) . Guidelines for making these switches are desirable because the PK profiles of both drugs may lead to overlap in exposure and PD interactions during the period immediately after switching. The QSP model used here provides valuable insights into benefits and risks associated with this transition process.
The QSP modeling outcomes suggest that starting PP1M immediately provides the best transition approach when compared to first transitioning to oral paliperidone for 1 week, followed by initiation of PP1M with or without an additional 1-week overlap with oral paliperidone. (See Table 2 for an overview.) The following predictions are generated by this model: 1) transitioning to PP1M from risperidone, aripiprazole, haloperidol, HALD, and AERIS is predicted to maintain or improve symptoms of psychosis as modeled with the PANSS total score after 1 week (oral risperidone and haloperidol), 2 weeks (oral aripiprazole), 4 weeks (HALD), and 8 weeks (AERIS); (2) switching from oral olanzapine may lead to a small reduction of antipsychotic efficacy in some patients; (3) in almost all cases, switching to PP1M decreases EPS liability (substantial in the case of haloperidol and haldol decanoate), but for most switches (except for haloperidol) increased D 2 R inhibition has the potential for increased prolactin synthesis; and (4) the potential for clinical complications, such as increases in psychotic symptoms, is most likely to occur transiently during the first weeks following introduction of PP1M (except for oral haloperidol and risperidone), especially when switching from aripiprazole or AERIS because of PD interactions.
Probability estimates for changes in psychotic symptoms have been expressed as PANSS total scores, the clinical scale used to calibrate the QSP model. It is somewhat unclear how to translate numerical changes in these scores into a probability for changes in psychotic symptoms. However, in general, increases in modeled PANSS total scores might be interpreted as a reduced antipsychotic treatment effect. EPS liability, on the other hand, has been calibrated using the fraction of patients prescribed anticholinergic medication in well-controlled clinical trials in schizophrenia and, therefore, represents a real probability for these motor side-effects.
The model outcomes are generally in line with observed clinical trial data with PP1M (Schreiner et al., 2017) , where improvements on efficacy and EPS liability were noted when switching from oral aripiprazole, risperidone, and olanzapine treatment that were considered "unsuccessful." In our model, we considered schizophrenia patients stable on "optimal" therapy, which might explain the difference in the case of olanzapine on efficacy. It would also suggest that the simulated improvements are underestimating the beneficial effects when switching from patients who are on a less ideal treatment plan. It is interesting to note that the model predicts the highest liability for prolactin increase with aripiprazole and that an increase in blood prolactin was noted in two patients previously on aripiprazole in the clinical trial. Fig. 4 . Changes in PANSS total score: (A) (more negative is better), EPS liability (B), and D 2 R inhibition as readout for prolactin synthesis side-effects (C) for different switching scenarios from 4 mg oral haloperidol (1 week oral paliperidone overlap, 2 weeks oral paliperidone overlap, and 0 weeks oral paliperidone overlap). (A) The data suggest the zero-week overlap (green curve) (i.e., starting PP1M immediately after the last dose of haloperidol) has the biggest efficacy regarding PANSS total score (more negative is better). (B) Similarly lower overall EPS liability is observed with the zero overlap, although all scenarios reduce EPS liability. (C) Overall D 2 R inhibition is increased most by the zero-overlap conditions; however, note that the D 2 R inhibition at time 0 (24 h after the last dose of haloperidol) is quite high already. Note also that after 4 weeks (3 weeks for the zero-overlap case) the clinical results are driven by PP1M alone. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
The model identifies a potential transient but substantial reduction in efficacy for a switch from oral olanzapine and aripiprazole (both oral and LAI). Interestingly, in the clinical trial (Schreiner et al., 2017) , patients on olanzapine had the highest frequency of psychotic disorder-related adverse events (6.9%). This underscores the importance of following these patients for a few weeks after switching.
An unexpected finding generated by the QSP switching model is the transient risk for worsening psychotic symptoms following discontinuation of aripiprazole. This prediction is likely due to the long half-life of aripiprazole and the nonlinear PD interactions between aripiprazole and PP1M, especially at lower doses of aripiprazole. Simulations of the D 2 R activity suggest that introducing a partial agonist with a relatively high affinity can displace the full antagonist present and reduce the overall antipsychotic efficacy of PP1M until aripiprazole is cleared. Several clinical reports support a possible worsening of psychotic symptoms after introduction of lower doses of aripiprazole to an existing Qualitative comparison between the three different switching scenarios for the individual antipsychotics. The optimal scenarios for each clinical readout are underlined. The critical period is an indication of the time that physicians should pay close attention to their patients during the transition. Changes in other clinical phenotypes are shown for the short period during transition (mostly 3 weeks for oral and 4 months for long-acting injectable antipsychotics) and the steady-state during when the first antipsychotic has completely disappeared. Paliperidone palmitate once-monthly (PP1M; direct switch), 1 week (1 week oral paliperidone before PP1M), 2 weeks (2 week oral paliperidone with PP1M starting at begin of week 2). antipsychotic (Takeuchi and Remington, 2013) . Similarly, a metaanalysis of trials where treatment was switched to aripiprazole found clinical worsening when the baseline antipsychotic was abruptly halted (Wisniewski and Robert, 2012) . This is in line with the predictions of the QSP model. Patients may be switched to LAI antipsychotics to achieve better efficacy, tolerability, or adherence. The QSP model allows for different clinical outcomes to be simulated in different switching scenarios, in principle allowing for tailored and individualized switching paradigms. However, these QSP computer modeling simulations have a number of limitations. The data used to calibrate the model came from industrysponsored clinical trials for which participants were highly selected and, therefore, might not reflect real-life situations with patients who might take additional medications or have other comorbid conditions. Furthermore, the changes in plasma levels of a particular antipsychotic are derived from average PK profile parameters and do not take into account confounding population parameters (e.g., age, body weight) (Bigos et al., 2008) , all of which could impact outcome in actual patients (Samtani et al., 2009) . Future application of the QSP model will incorporate these variable PK components in the platform to further personalize the switching paradigm or simulate virtual patient groups for a general estimation based on confidence intervals derived from population PK models. For these reasons, the symptomatic changes currently predicted by the QSP model must be regarded as more relevant to the overall schizophrenia population but may not hold true for particular patients.
Once validated, the QSP model can be used to derive optimal switching scenarios for all antipsychotics on the market, without needing to perform the clinical trial and providing a guideline frame of reference to the practicing physician.
In summary, this report considers how computer-based modeling can be informative for optimizing the switching paradigm to PP1M. The computer simulations consistently showed immediate switch to PP1M as the optimal switching approach. Nevertheless, unique individual characteristics require clinical watchfulness in the initial weeks following switching. Further enhancement of the QSP model should include individual patient variability and the development of additional cognitive readout to permit dissemination of consequences of switching scenarios for these clinical symptoms (Table 2) .
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